Supernus Pharmaceuticals (SUPN) Beats Q4 Earnings and Revenue Estimates

Group 1: Earnings Performance - Supernus Pharmaceuticals reported quarterly earnings of $0.75 per share, exceeding the Zacks Consensus Estimate of$ 0.52 per share, and significantly up from $0.02 per share a year ago, representing an earnings surprise of 44.23% [1] - The company posted revenues of$ 174.16 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 12.18%, compared to year-ago revenues of $164.31 million [2] - Over the last four quarters, Supernus has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Group 2: Stock Performance and Outlook - Supernus shares have declined approximately 9.6% since the beginning of the year, while the S&P 500 has gained 1.7% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is$ 0.36 on revenues of $143.75 million, and for the current fiscal year, it is$ 1.93 on revenues of $622.79 million [7] Group 3: Industry Context - The Medical - Generic Drugs industry, to which Supernus belongs, is currently ranked in the bottom 30% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The estimate revisions trend for Supernus is currently favorable, resulting in a Zacks Rank 1 (Strong Buy) for the stock, indicating expectations of outperforming the market in the near future [6]